Nuo Therapeutics, Inc. financial data

Symbol
AURX on OTC
Industry
Surgical & Medical Instruments & Apparatus
Location
8285 El Rio, Suite 150, Houston, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
CYTOMEDIX INC (to 10/8/2014), AUTOLOGOUS WOUND THERAPY INC (to 4/10/2000), AUTOLOGOUS WOUND TRERAPY INC (to 3/23/2000)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 178 % -30.3%
Quick Ratio 28.4 % -15.7%
Debt-to-equity 119 % +59.2%
Return On Equity -347 % -17.8%
Return On Assets -158 % +5.98%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 46.6M shares +10.1%
Common Stock, Shares, Outstanding 46.6M shares +10.1%
Entity Public Float 35.9M USD +102%
Common Stock, Value, Issued 4.66K USD +10.1%
Weighted Average Number of Shares Outstanding, Basic 45.6M shares +8.24%

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) -2.48M USD +28.7%
Nonoperating Income (Expense) -794 USD +27%
Net Income (Loss) Attributable to Parent -2.48M USD +28.7%
Earnings Per Share, Basic -0.06 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 684K USD +17.4%
Accounts Receivable, after Allowance for Credit Loss, Current 329K USD +41.4%
Inventory, Net 168K USD -20%
Assets, Current 1.34M USD +6.7%
Property, Plant and Equipment, Net 189K USD +286%
Operating Lease, Right-of-Use Asset 188K USD -35.8%
Assets 1.72M USD +7.45%
Accounts Payable, Current 385K USD -3.86%
Accrued Liabilities, Current 264K USD +34.6%
Liabilities, Current 714K USD +4.2%
Operating Lease, Liability, Noncurrent 115K USD -39%
Liabilities 829K USD -5.09%
Retained Earnings (Accumulated Deficit) -31.8M USD -8.47%
Stockholders' Equity Attributable to Parent 890K USD +22.5%
Liabilities and Equity 1.72M USD +7.45%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -562K USD +29.3%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 46.6M shares +10.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -562K USD +29.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 684K USD +7.25%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.21K USD +63.7%
Deferred Tax Assets, Valuation Allowance 41.3M USD -0.91%
Deferred Tax Assets, Gross 41.3M USD -0.91%
Operating Lease, Liability 179K USD -35.1%
Depreciation 15.3K USD +6.6%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 204K USD -37.2%
Property, Plant and Equipment, Gross 610K USD +34.1%
Operating Lease, Liability, Current 64.6K USD -26.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 82.7K USD +3.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 80.3K USD -28.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 24.4K USD -49.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 21.3K USD -74.3%
Deferred Tax Assets, Operating Loss Carryforwards 40.9M USD -0.77%
Preferred Stock, Shares Authorized 1M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 21.3K USD -74.3%
Additional Paid in Capital 32.6M USD +8.81%
Share-based Payment Arrangement, Expense 32.5K USD +220%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%